NEW YORK (GenomeWeb News) – Epigenomics said that it has reached a financing agreement with YA Global Master SPV for up to €5 million ($6.7 million).

Under the terms of the agreement, YA Global will purchase over two years convertible notes with a total nominal amount of €5 million at a purchase price of 95 percent of the nominal amount. Epigenomics may issue the notes in tranches of €500,000 each, with each tranche comprising 500 convertible notes in the form of bearer bonds each with a nominal value of €1,000. The bonds are transferable only with approval by Epigenomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.